Findings presented during the developmental
therapeutics session at the ASCO 2020 Virtual Scientific
Program
NantHealth, Inc. (NASDAQ: NH), a next-generation,
evidence-based, personalized healthcare company, announced the
publication of four abstracts on developmental therapeutics for
immunotherapy, molecularly targeted agents and tumor biology during
the American Society of Clinical Oncology (ASCO) 2020 Virtual
Scientific Program.
The program, held virtually from May 29-31, 2020, gathered
oncology physicians, biotechnology executives, researchers, patient
advocates, and investment analysts to discuss cutting-edge clinical
research and therapeutics in oncology, and to gain insights for
improving cancer care.
Alongside ImmunityBio, LLC, and others, Dr. Sandeep K. Reddy,
Chief Medical Officer at NantHealth, and Christopher Szeto,
Director of Machine Learning at NantHealth, presented the data
gathered from NantHealth’s database which was used to advance
findings in developmental therapeutics.
The details of NantHealth’s ASCO posters are as follows:
Title: “Effect of chemokine signaling signatures on
resolving discrepancy between TMB and checkpoint expression”
Authors: Saihitha Veerapaneni, Rahul Parulkar, Sandeep K.
Reddy, Shahrooz Rabizadeh, Stephen Charles Benz and Christopher
Szeto; ImmunityBio, LLC, Culver City, CA; NantHealth, Culver City,
CA Abstract Number: 3131 Session Title: Developmental
Therapeutics—Immunotherapy
“In this study, 1,395 clinical samples from the NantHealth
database with matched tumor normal whole exomes and deep
whole-transcriptomic sequencing were analyzed to confirm previous
findings that Tumor Mutation Burden (TMB) and PDL1 mRNA were not
correlated,” said Dr. Sandeep K. Reddy, Chief Medical Officer,
NantHealth. “However, chemokine activity may be an alternative to
TMB and PDL1 to identify patients appropriate for immunotherapy and
can help resolve discordant cases.”
Title: “Targetable immune checkpoint molecules may be
significantly differentially expressed in minority ethnicities”
Authors: Jacob J. Adashek, Christopher Szeto, J. Zack
Sanborn, Sandeep K. Reddy, Amir A. Toor, Stamatina Danielides,
Steven Smith, Steven R. Grossman, Charles V Clevenger, Anthony
Faber, Andrea Ferreira-Gonzalez, Sosipatros Alexandros Boikos;
University of South Florida, H. Lee Moffitt Cancer Center &
Research Institute, Tampa, FL; NantHealth, Culver City, CA
Abstract Number: 3576 Session Title: Developmental
Therapeutics—Molecularly Targeted Agents and Tumor Biology
“The Cancer Genome Atlas (TCGA) data for 7,087 patients and
about 2,700 patients in the NantHealth database were used to
identify differential patterns of checkpoint gene expression across
different ethnic groups,” said Dr. Sandeep K. Reddy, Chief Medical
Officer, NantHealth. “White breast cancer patients might be
anticipated to exhibit reduced sensitivity to PD1/CTLA4 blockade,
while Black colon cancer patients may exhibit reduced sensitivity
to IDO1 therapies, such as epacadostat. Ethnicity may represent a
significant factor for efficacy checkpoint blockade therapies.”
Title: “Highly accurate automated tissue classification
using deep learning on digital pathology images: A novel tool for
resolving conflicts in diagnosis” Authors: Liudmila
Beziaeva, Mustafa Jaber, Stephen Charles Benz, Shahrooz Rabizadeh,
and Christopher Szeto, ImmunityBio, LLC, Culver City, CA;
NantHealth, Culver City, CA Abstract Number: 3578 Session
Title: Developmental Therapeutics—Molecularly Targeted Agents
and Tumor Biology
“NantHealth combined whole slide imaging with deep neural
networks to develop a tool which can identify which of 24 primary
tumor types a sample is derived from with 94.6 percent accuracy,”
said Christopher Szeto, Director of Machine Learning, NantHealth.
“This accuracy, which approaches that of a human pathologist, is
achieved by focusing machine-vision attention on just tumor regions
within bulk samples. Used in conjunction with molecular profiling,
rates of Cancers of Unknown Primary (CUP) or misdiagnosis can
feasibly be minimized to improve patient care.”
Title: “High correlation between TMB, expressed TMB, and
neoantigen load using tumor: Normal whole exome DNA and matched
whole transcriptome RNA sequencing” Authors: Christopher
Szeto, Mrinal M. Gounder, Rahul Parulkar, Andrew Nguyen, Shahrooz
Rabizadeh, Sandeep K. Reddy; Memorial Sloan Kettering Cancer
Center, New York, NY; ImmunityBio, LLC, Culver City, CA;
NantHealth, Culver City, CA Abstract Number: e15238
Session Title: Publication Only: Developmental
Therapeutics—Immunotherapy
“Surprisingly, we see minimal difference between the various
biomarkers derived from mutational burden,” said Christopher Szeto,
Director of Machine Learning, NantHealth. “Tissue-specific TMB
thresholds may be useful in patient with Sarcoma and Pancreatic
cancers. Otherwise, additional data inputs such as microbiome,
chemokine expression, and TME cell phenotyping may be required to
improve upon TMB as a biomarker of immunotherapy response.”
About NantHealth, Inc.
NantHealth, a member of the NantWorks ecosystem of companies,
provides leading solutions across the continuum of care for
physicians, payers, patients and biopharmaceutical organizations.
NantHealth enables the use of cutting-edge data and technology
toward the goals of empowering clinical decision support and
improving patient outcomes. NantHealth’s comprehensive product
portfolio combines the latest technology in payer/provider
platforms that exchange information in near-real time (NaviNet and
Eviti), and molecular profiling services that combine comprehensive
DNA & RNA tumor-normal profiling with pharmacogenomics analysis
(GPS Cancer®). For more information, please visit nanthealth.com or
follow us on Twitter, Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200618005885/en/
NANT Jen Hodson Jen@nant.com 562-397-3639
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2023 to Apr 2024